The Delhi High Court sought Novo Nordisk’s response on why its patent on semaglutide should not be revoked, based on a petition filed by Hyderabad-based Natco Pharma. Justice Jyoti Singh issued notice to Novo Nordisk and listed the petition for further hearing in February. Natco Pharma claimed the patent lacked novelty and alleged an attempt to evergreen the patent to extend exclusivity beyond the primary patent’s expiry. Novo Nordisk’s semaglutide patent is set to expire in March, and multiple generic companies are attempting to manufacture their own versions, leading to patent disputes in India.